Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer-Reference-Cited by-同舟云学术

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer

Published:2019-12-04 Issue:521 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Li Yanjing¹^ORCID,He Yiping¹^ORCID,Butler William¹^ORCID,Xu Lingfan¹²,Chang Yan¹³,Lei Kefeng¹⁴^ORCID,Zhang Hong¹^ORCID,Zhou Yinglu¹^ORCID,Gao Allen C.⁵,Zhang Qingfu¹⁶^ORCID,Taylor Daniel G.⁷^ORCID,Cheng Donghui⁸,Farber-Katz Suzette⁹^ORCID,Karam Rachid⁹^ORCID,Landrith Tyler⁹,Li Bing⁹^ORCID,Wu Sitao⁹^ORCID,Hsuan Vickie⁹^ORCID,Yang Qing¹⁰^ORCID,Hu Hailiang¹^ORCID,Chen Xufeng¹^ORCID,Flowers Melissa¹^ORCID,McCall Shannon J.¹^ORCID,Lee John K.¹¹¹²,Smith Bryan A.⁸,Park Jung Wook⁸^ORCID,Goldstein Andrew S.⁷¹³¹⁴^ORCID,Witte Owen N.⁸¹³¹⁵^ORCID,Wang Qianben¹^ORCID,Rettig Matthew B.¹¹¹⁴¹⁶^ORCID,Armstrong Andrew J.¹⁷^ORCID,Cheng Qing¹⁸^ORCID,Huang Jiaoti¹^ORCID

Affiliation:

1. Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.

2. Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.

3. Department of Pharmacology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, China.

4. General Surgery, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Zhejiang 310014, China.

5. Department of Urology and Cancer Center, University of California Davis School of Medicine, Sacramento, CA 95616, USA.

6. Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang 110122, China.

7. Department of Molecular, Cellular, Developmental Biology, University of California, Los Angeles, CA 90095, USA.

8. Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

9. Ambry Genetics, Aliso Viejo, CA 92656, USA.

10. School of Nursing, Duke University, Durham, NC 27710, USA.

11. Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

12. Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA.

13. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.

14. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

15. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.

16. VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.

17. Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.

18. Department of Surgery, Duke University School of Medicine, Durham NC27710, USA.

Abstract

Cellular heterogeneity of PCa contributes to hormonal therapy failure, but CXCR2 on neuroendocrine cells is a potential therapeutic target.

Funder

NIH Clinical Center

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference33 articles.